ELCC 2016 | Progress in the treatment of ALK-positive non-small cell lung cancer

David Carbone

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, provides an overview of the improvements in the treatment of patients with non-small cell lung cancer (NSCLC) carrying the anaplastic lymphoma kinase (ALK) gene rearrangement, including ALK-targeted therapies with improved blood–brain barrier penetrance and understanding of resistance mechanisms.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter